As of November 6, 2026, 3 holders' latest Schedule 13D or 13G filings report owning 5% or more of Matinas BioPharma Holdings, Inc. The largest reported stake is Sanitam Partners LLC's, at 9.99%. 6 filings are on record since August 14, 2025 (Schedule 13D/A, August 13, 2026).
Who owns Matinas BioPharma Holdings, Inc.?
Sell to companies like Matinas BioPharma Holdings, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sanitam Partners LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13D/A, 2026-08-13
- · Reporting person: Hezbay Holdings LLC · Sole voting: 1,306,488 · Shared voting: 0 · Sole dispositive: 1,306,488 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-14
- · Reporting person: Highbridge Capital Management, LLC · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2025-11-14
- · Holder: Hezbay Holdings LLC · Percent: 4.99% · SCHEDULE 13D/A
- · Holder: Lazar David E. · Percent: 9.81% · SCHEDULE 13G
Matinas BioPharma Holdings, Inc. has 6 Schedule 13D or 13G filings on record since 2025-08-14. 3 holders' latest filing reports 5% or more of common stock, $0.0001 par value per share. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| Sanitam Partners LLC | 9.99% | 0 | SCHEDULE 13D/A, 2026-08-13 | 2026-06-10 |
| 9.81% | 545,000 | SCHEDULE 13G, 2025-08-19 | 2025-08-15 | |
| Hezbay Holdings LLC | 9.54% | 1,306,488 | SCHEDULE 13G, 2026-07-14 | 2026-07-13 |
| Highbridge Capital Management, LLC | 0% | 0 | SCHEDULE 13G/A, 2025-11-14 | 2025-09-30 |
Holding shares or following this stake? See who's behind Matinas BioPharma Holdings, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Matinas BioPharma Holdings, Inc. and the records around it.
Matinas BioPharma Holdings, Inc. elsewhere on the record
- Leadership changes Jul 2026
- Who owns it
Companies that share a holder
- Lazar David E. also filed stake reports on 8 other companies: HIGHWAY HOLDINGS LTD (Nov 2026), Aterian, Inc. (Sep 2026), MAINZ BIOMED N.V. (Aug 2026)
- Highbridge Capital Management, LLC also filed stake reports on 83 other companies: Aeon Acquisition I Corp. (Aug 2026), Alpex Acquisition Corp (Aug 2026), Aperture AC (Aug 2026)
Watch Matinas BioPharma Holdings, Inc.
Get an email when Matinas BioPharma Holdings, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Matinas BioPharma Holdings, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Matinas BioPharma Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Matinas BioPharma Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sanitam Partners LLC | 0 | 0 | 0 | 0 | SCHEDULE 13D/A, 2026-08-13 |
| Stern Adam K | 2,972,524 | 0 | 2,972,524 | 0 | SCHEDULE 13D/A, 2026-08-13 |
| Hezbay Holdings LLC | 1,306,488 | 0 | 1,306,488 | 0 | SCHEDULE 13G, 2026-07-14 |
| Highbridge Capital Management, LLC | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2025-11-14 |
The latest filing identifies Matinas BioPharma Holdings, Inc. by CUSIP 576810303 and gives its principal executive office as 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER, NJ 07921 (SCHEDULE 13D/A, 2026-08-13).
Source of funds (Item 3)
Item 3 of the Schedule 13D is hereby amended and supplemented by the addition of the following: On October 31, 2025, Mr. Stern caused SternAegis DBP to exercise Warrants to purchase 92,100 shares of Common Stock at a price of $0.6446 per share using the Warrant's cashless exercise mechanism. On July 10, 2026, Mr. Stern caused (i) AKSLP to exercise Warrants to purchase 344,710 shares of Common Stock and (ii) SternAegis DBP to exercise Warrants to purchase 630,335 shares of Common Stock, each at a price of $0.35 per share using personal funds, as further described in Item 5(c).Sanitam Partners LLC, SCHEDULE 13D/A, 2026-08-13
Purpose of Transaction (Item 4)
Sanitam Partners LLC
Item 4 of the Schedule 13D is hereby amended and supplemented by the addition of the following: The Reporting Persons' response to Item 5(c) is incorporated by reference into this Item 4.Item 4 of the SCHEDULE 13D/A filed 2026-08-13
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-14 | Highbridge Capital Management, LLC | 8.4% | SCHEDULE 13G/A |
| 2025-08-19 | Lazar David E. | 9.81% | SCHEDULE 13G |
| 2025-09-25 | Hezbay Holdings LLC | 4.99% | SCHEDULE 13D/A |
| 2025-11-14 | Highbridge Capital Management, LLC | 0% | SCHEDULE 13G/A |
| 2026-07-14 | Hezbay Holdings LLC | 9.54% | SCHEDULE 13G |
| 2026-08-13 | Sanitam Partners LLC | 9.99% | SCHEDULE 13D/A |
Questions about who owns Matinas BioPharma Holdings, Inc.
Who owns Matinas BioPharma Holdings, Inc.?
On this page, 3 holders' latest ownership filings report 5% or more of Matinas BioPharma Holdings, Inc.: Sanitam Partners LLC (9.99%, Schedule 13D/A, filed 2026-08-13), Lazar David E. (9.81%, Schedule 13G, filed 2025-08-19) and Hezbay Holdings LLC (9.54%, Schedule 13G, filed 2026-07-14).
Who are the largest shareholders of Matinas BioPharma Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Matinas BioPharma Holdings, Inc. on this page are Sanitam Partners LLC (9.99%), Lazar David E. (9.81%) and Hezbay Holdings LLC (9.54%).
When did Sanitam Partners LLC buy into Matinas BioPharma Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Sanitam Partners LLC on this page is the Schedule 13D/A, filed 2026-08-13, reporting 9.99%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Matinas BioPharma Holdings, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 13, 2026 | Leadership change: Robin L. Smith departs | — | Leadership changes | Source |
| February 19, 2025 | Form D, private offering | $1.65M sold | Form D page | Source |
Tools for this story
Each opens in a new tab, filled in for Matinas BioPharma Holdings, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.